Back to Search
Start Over
Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy.
- Source :
- In Vivo; Jan/Feb2020, Vol. 34 Issue 1, p239-245, 7p
- Publication Year :
- 2020
-
Abstract
- Background: Low-grade fibromyxoid sarcoma (LGFMS) is a rare sarcoma subtype with a generally indolent pattern of clinical behaviour, but treatments for advanced disease are limited. Patients and Methods: A retrospective search of a prospectively maintained institutional database identified 102 patients treated from December 1994 to August 2018. We evaluated the outcome of patients and the efficacy and safety of non-surgical therapies in LGFMS. Results: Ninety-four out of 102 (92.2%) underwent primary resection, seven (6.9%) were treated with systemic therapy and one (1.0%) is currently being treated with pre-operative radiotherapy. The RECIST 1.1 response rate to first-line chemotherapy was 0%, and median progression-free survival was 1.84 months (95% confidence intervaI=0.10-3.6 months). Conclusion: Conventional systemic therapy has limited efficacy in advanced LGFMS. [ABSTRACT FROM AUTHOR]
- Subjects :
- SARCOMA
CANCER chemotherapy
CHROMOSOMAL translocation
RADIOTHERAPY
Subjects
Details
- Language :
- English
- ISSN :
- 0258851X
- Volume :
- 34
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- In Vivo
- Publication Type :
- Academic Journal
- Accession number :
- 142303672
- Full Text :
- https://doi.org/10.21873/invivo.11766